시장보고서
상품코드
1628896

세계의 피부암 진단 시장 : 검사 유형별, 암 유형별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모 및 점유율, 예측(2024-2032년)

Skin Cancer Diagnostics Market, By Test Type, By Cancer Type, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 269 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

리포트 하이라이트

피부암 진단 시장 규모는 2023년에 91억 1,450만 달러에 달하며, 2024-2032년에 CAGR 5.90%로 확대

피부암 진단 시장 역학

피부암 이환율의 상승

피부암은 최근 수십년간 가장 흔한 암 중 하나이며, 흑색종과 비흑색종 모두 피부암이 더 흔해지고 있습니다. 세계보건기구(WHO)에 따르면 2020년에는 150만 명 이상의 새로운 피부암 환자가 보고될 것으로 예상됩니다. 또한 유럽연합 집행위원회의 보고서에 따르면 2020년 EU-27의 신규 암 진단 중 피부 흑색종이 차지하는 비율은 4%%였습니다. 또한 암으로 인한 전체 사망자의 1.3%을 차지합니다. 피부암은 유럽에서 6번째로 많이 진단되는 악성 종양입니다. 세계의 피부암 진단 시장은 피부암을 포함한 다른 암의 유병률이 전 세계에서 증가함에 따라 예측 기간 중 확대될 것으로 예상됩니다.

피부암 진단 시장 : 주요 인사이트

당사의 리서치 애널리스트들이 공유한 분석에 따르면 세계의 피부암 진단 시장은 예측 기간(2024-2032년) 동안 약 5.90%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예상됩니다.

검사 유형별로는 피부 생검 카테고리가 2023년에 가장 높은 시장 점유율을 보였습니다.

암 유형별로는 2023년 비흑색종이 주요 부문으로 부상했습니다.

지역별로는 북미가 2023년 매출 1위를 차지했습니다.

피부암 진단 시장 : 세분화 분석

세계의 피부암 진단 시장은 검사 유형, 암 유형, 최종사용자, 지역별로 분류됩니다.

검사 유형별로는 림프절 생검, 피부경 검사, 영상 검사, 피부 생검, 기타로 구분됩니다. 피부 생검 부문이 2023년 시장 점유율의 대부분을 차지했습니다. 피부 생검은 신체에서 소량의 피부 조직을 채취하는 의료 기술로서 가장 널리 사용되는 검진 재료입니다. 피부 생검은 정확성, 신뢰성, 적응성으로 인해 피부암 진단의 황금 표준입니다. 또한 효율적인 피부암 검진 및 치료에 필수적입니다. 피부 생검의 필요성이 크게 증가하고 있으며, 향후 수년간 계속 증가할 것으로 예상됩니다. 우려되는 피부 병변을 현미경으로 검사할 수 있으므로 이 과정을 통해 결정적인 진단을 내릴 수 있습니다. 또한 피부암의 유형, 병기 및 중증도와 같은 속성, 병변의 악성 여부를 판단하는 데도 도움이 됩니다.

최종사용자별로 시장은 병원 및 클리닉, 연구소, 기타로 구분되며, 2023년 시장 점유율은 병원 및 클리닉이 피부암 진단 산업을 지배할 것으로 예상됩니다. 예측 기간 중 이 분야는 가장 빠른 속도로 증가할 것으로 예상됩니다. 피부암 유병률 증가, 진단 툴의 개선, 조기 진단에 대한 인식 증가 등이 피부암 진단 시장의 성장에 기여하고 있습니다. AI와 원격 피부치료(teledermatology)를 병원에 통합하여 진단의 접근성과 정확성을 더욱 향상시킬 수 있는 병원 기반 피부암 진단 서비스에 대한 수요가 증가할 것으로 예상됩니다.

피부암 진단 시장 : 지역별 분석

지역적으로 피부암 진단 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카에 분포되어 있습니다. 이 지역은 비즈니스를 가져 오는 국가에 따라 더 세분화됩니다.

2023년 북미 피부암 진단 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 북미 피부암 진단 시장은 이 지역에서 활동하는 주요 기업(Dermlite LLC, Castle Biosciences Inc., Dermtech Inc. 등)이 피부암 진단 제품 연구개발에 많은 비용을 지출하고 있으므로 북미 피부암 진단 시장이 크게 성장하고 있습니다. 또한 흑색종 발병률의 급격한 증가로 인해 시장이 확대되고 있습니다. 또한 북미는 피부암 진단 개발을 선도하고 있으며, 이는 이 지역 산업에 큰 잠재력을 가지고 있습니다.

피부암 진단 시장은 자외선 노출과 같은 환경 변수 증가, 피부암에 대한 인식 증가, 진단 기술 향상으로 인해 아시아태평양에서 가장 빠른 속도로 발전할 것으로 예상됩니다. 피부암의 조기 발견 및 치료를 장려하는 정부 프로그램과 함께 의료비 상승과 의료 시설에 대한 접근성 용이성이 시장 확대를 더욱 촉진하고 있습니다. 또한 아시아태평양에서는 이러한 피부암 치료제에 대한 규제 당국의 승인과 아시아태평양의 신흥 국가 시장의 대규모 미개발 시장 존재가 아시아태평양의 피부암 진단 시장 확대를 촉진할 것으로 예상됩니다.

피부암 진단 시장 : 경쟁 구도

피부암 진단 시장의 주요 기업으로는 FOUNDATION MEDICINE, INC., Castle Bioscience, DermTech, bioMerieux Inc. 주요 기업은 높은 품질 기준을 유지하는 것을 우선시하고, 이 지역의 현재 소비자 기반을 활용하여 큰 시장에 접근할 수 있는 기회를 얻고 있습니다. 시장에서 신뢰성을 구축한 브랜드는 이 전략의 혜택을 누릴 수 있습니다. 이러한 기업은 대량의 샘플을 효율적으로 처리하고 분석할 수 있는 최첨단 인프라와 기술에 많은 투자를 하고 있습니다. 시장에서의 입지를 강화하기 위해 기업은 유통업체 및 기타 기업과 전략적 제휴를 맺기도 합니다. 예를 들어 진단 기술 개발 기업 SkylineDx는 2024년 1월 유럽 특허 제3827101호를 취득하여 암 진단 및 맞춤 치료 분야에서 획기적인 진전을 이루었습니다. 이 특허는 유전자 발현 시그니처 수준을 사용하여 원발성 피부 흑색종 환자를 분류하고 치료하는 새로운 기술을 설명합니다.

목차

제1장 피부암 진단 시장 개요

  • 조사 범위
  • 시장 추정 기간

제2장 개요

  • 시장 내역
  • 경쟁 인사이트

제3장 피부암 진단의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장의 향후 동향

제4장 피부암 진단 시장 : 산업 분석

  • PEST 분석
  • Porter's Five Forces 분석
  • 시장 성장 전망 : 지도제작
  • 규제 체제 분석

제5장 피부암 진단 시장 : COVID-19의 영향 분석

  • COVID-19 이전의 영향 분석
  • COVID-19 이후의 영향 분석

제6장 피부암 진단 시장 구도

  • 피부암 진단 시장 점유율 분석(2023년)
  • 주요 제조업체별 내역 데이터
    • 기존 기업의 분석
    • 신규 기업의 분석

제7장 피부암 진단 시장 : 검사 유형별

  • 개요
    • 부문별 점유율 분석 : 검사 유형별
    • 림프절 생검
    • 피부경 검사
    • 영상 검사
    • 피부 생검
    • 기타

제8장 피부암 진단 시장 : 암 유형별

  • 개요
    • 부문별 점유율 분석 : 암 유형별
    • 악성 흑색종
    • 비흑색종

제9장 피부암 진단 시장 : 최종사용자별

  • 개요
    • 부문별 점유율 분석 : 최종사용자별
    • 병원·진료소
    • 연구소
    • 기타

제10장 피부암 진단 시장 : 지역별

  • 서론
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양의 주요 제조업체
    • 인도
    • 중국
    • 한국
    • 일본
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제11장 주요 벤더 분석 : 피부암 진단 업계

  • 경쟁 대시보드
  • 기업 개요
    • FOUNDATION MEDICINE, INC.
    • Castle Bioscience
    • DermTech
    • bioMerieux Inc.
    • DermaSensor, Inc.
    • Quest Diagnostics Incorporated.
    • NeoGenomics Laboratories
    • SkylineDx
    • Abbott
    • F Hoffmann-La Roche Ltd
    • Others

제12장 AnalystView의 전방위적 분석

KSA 25.02.11

REPORT HIGHLIGHT

Skin Cancer Diagnostics Market size was valued at USD 9,114.5 Million in 2023, expanding at a CAGR of 5.90% from 2024 to 2032.

The procedure for identifying and diagnosing skin cancer is called skin cancer diagnostics. This encompasses a number of methods, including molecular pathology, histology, immunohistochemistry, electron microscopy, physical examination, and biopsy. Among the cancers that impact the skin is skin cancer. Skin cancer comes in three primary forms: squamous cell carcinoma, malignant melanoma, and basal cell carcinoma. Globally, the incidence of skin cancer is rising due to factors including ageing populations and prolonged UV exposure, which is driving the market for skin cancer diagnostics. This is driving the need for efficient diagnostic tools. Furthermore, more people are being encouraged to have regular tests for skin cancer due to rising public awareness and educational initiatives regarding the significance of early diagnosis.

Skin Cancer Diagnostics Market- Market Dynamics

Rising Incidence of Skin Cancer

Skin cancer has been one of the most common types of cancer in recent decades, with both melanoma and non-melanoma skin cancers becoming more common. Over 1.5 million new instances of skin cancer were anticipated to be reported in 2020, according to the World Health Organization (WHO). In addition, the European Commission reports that in 2020, cutaneous melanoma accounted for 4% of all new cancer diagnoses in the EU-27. It was also responsible for 1.3% of all deaths from cancer. Skin cancer is the sixth most often diagnosed malignancy in Europe. The global market for skin cancer diagnostics is expected to expand throughout the forecast period as the prevalence of other cancers, including skin cancer, rises worldwide.

Skin Cancer Diagnostics Market- Key Insights

As per the analysis shared by our research analyst, the global Skin Cancer Diagnostics Market is estimated to grow annually at a CAGR of around 5.90% over the forecast period (2024-2032)

Based on test type segmentation, the skin biopsy category was predicted to show maximum market share in the year 2023

Based on cancer type segmentation, the non-melanoma was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Skin Cancer Diagnostics Market- Segmentation Analysis:

The Global Skin Cancer Diagnostics Market is segmented on the basis of Test Type, Cancer Type, End-user, and Region.

Based on test type, the market is segmented into Lymph Node Biopsy, Dermatoscopy, Imaging Tests, Skin Biopsy, and Others. The skin biopsy segment accounted for the majority of the market share in 2023. The most popular material for screening is skin biopsy, a medical technique in which a small sample of skin tissue is taken from the body. Skin biopsy is the gold standard for skin cancer diagnosis because of its precision, dependability, and adaptability. It is also essential for efficient skin cancer screening and treatment. The need for skin biopsies has increased significantly and is anticipated to continue to rise over the next several years. Because the worrisome skin lesion can be examined under a microscope, the process also yields a conclusive diagnosis. In addition, it assists in determining the type of skin cancer and its attributes, including stage and severity, as well as whether the lesion is malignant.

By end-user, the market is segmented into hospitals and clinics, laboratories, and others. With a significant market share in 2023, hospitals and clinics dominated the skin cancer diagnostics industry. Throughout the forecast period, this segment is also anticipated to increase at the fastest rate. The rising prevalence of skin cancer, improvements in diagnostic tools, and growing awareness of early diagnosis are all factors contributing to the skin cancer diagnostics market growth. The need for hospital-based skin cancer diagnostic services can be increased by integrating AI and teledermatology in hospitals, which can further improve diagnostic accessibility and accuracy.

Skin Cancer Diagnostics Market- Geographical Insights

Geographically, the Skin Cancer Diagnostics Market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

In 2023, North America's share in the regional skin cancer diagnostics market was the greatest. Due to significant expenditures made in the research and development of skin cancer diagnostics products by leading companies operating in the region, including Dermlite LLC, Castle Biosciences Inc., and Dermtech Inc., the North American skin cancer diagnostics market has experienced significant expansion. Additionally, the market is growing due to the sharp rise in melanoma incidence. Furthermore, North America is leading the way in the development of skin cancer diagnostics, which offers significant potential prospects for the region's industry.

The market for skin cancer diagnostics is expected to develop at the quickest rate in the Asia Pacific due to rising environmental variables like UV exposure, growing awareness of skin cancer, and improvements in diagnostic technology. Along with government programs encouraging early identification and treatment of skin cancer, rising healthcare costs and easier access to medical facilities further fuel market expansion. Additionally, it is projected that the regulatory approvals for these skin cancer medications in the Asia Pacific, together with the existence of a sizable and underdeveloped market in the region's developing nations, will support the expansion of the skin cancer diagnostics market in Asia Pacific.

Skin Cancer Diagnostics Market- Competitive Landscape:

Among the top companies in the skin cancer diagnostics market are FOUNDATION MEDICINE, INC., Castle Bioscience, DermTech, bioMerieux Inc., DermaSensor, Inc., and others. Important firms are prioritizing upholding high standards of quality and gaining access to a sizable market by using the region's current consumer bases. Brands that have established credibility in the marketplace can benefit from this tactic. These companies are making significant investments in cutting-edge infrastructure and technology, which enables them to process and analyze a high volume of samples efficiently. In order to increase their market presence, businesses also engage in a number of strategic activities with distributors and other businesses. For instance, the diagnostics technology developer SkylineDx was granted European Patent No. 3827101 in January 2024, marking a breakthrough in cancer diagnosis and tailored therapy. Using gene expression signature levels, the patent describes new techniques for classifying and treating individuals with primary cutaneous melanoma.

Recent Developments:

February 2024: MelaNodal Predict, a very sophisticated predictive gene expression test, was introduced by Quest Diagnostics to assist in customizing treatment choices for patients with melanoma, a type of skin cancer and one of the most prevalent diseases in the United States.

January 2024: DermaSensor Inc. was granted FDA approval for its noninvasive skin cancer assessment system, which employs artificial intelligence to identify common skin malignancies like SCC, basal cell carcinoma, and melanoma. Using an FDA-approved algorithm, the wireless, handheld gadget gives quick, objective data, enabling doctors to assess suspected lesions without the need for intrusive treatments.

April 2023: SkylineDx and NeraCare GmbH announced that they will work together to create a test that would allow life science businesses to launch critical melanoma treatments more quickly.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SKIN CANCER DIAGNOSTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • FOUNDATION MEDICINE, INC.
  • Castle Bioscience
  • DermTech
  • bioMerieux Inc.
  • DermaSensor, Inc.
  • Quest Diagnostics Incorporated.
  • NeoGenomics Laboratories
  • SkylineDx
  • Abbott
  • F Hoffmann-La Roche Ltd
  • Others

GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY TEST TYPE- MARKET ANALYSIS, 2019 - 2032

  • Lymph Node Biopsy
  • Dermatoscopy
  • Imaging Tests
  • Skin Biopsy
  • Others

GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE- MARKET ANALYSIS, 2019 - 2032

  • Melanoma
  • Non-Melanoma

GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals and Clinics
  • Laboratories
  • Others

GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Skin Cancer Diagnostics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Skin Cancer Diagnostics Market Snippet by Test Type
    • 2.1.2. Skin Cancer Diagnostics Market Snippet by Cancer Type
    • 2.1.3. Skin Cancer Diagnostics Market Snippet by End-user
    • 2.1.4. Skin Cancer Diagnostics Market Snippet by Country
    • 2.1.5. Skin Cancer Diagnostics Market Snippet by Region
  • 2.2. Competitive Insights

3. Skin Cancer Diagnostics Key Market Trends

  • 3.1. Skin Cancer Diagnostics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Skin Cancer Diagnostics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Skin Cancer Diagnostics Market Opportunities
  • 3.4. Skin Cancer Diagnostics Market Future Trends

4. Skin Cancer Diagnostics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Skin Cancer Diagnostics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Skin Cancer Diagnostics Market Landscape

  • 6.1. Skin Cancer Diagnostics Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Skin Cancer Diagnostics Market - By Test Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Test Type, 2023 & 2032 (%)
    • 7.1.2. Lymph Node Biopsy
    • 7.1.3. Dermatoscopy
    • 7.1.4. Imaging Tests
    • 7.1.5. Skin Biopsy
    • 7.1.6. Others

8. Skin Cancer Diagnostics Market - By Cancer Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cancer Type, 2023 & 2032 (%)
    • 8.1.2. Melanoma
    • 8.1.3. Non-Melanoma

9. Skin Cancer Diagnostics Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
    • 9.1.2. Hospitals and Clinics
    • 9.1.3. Laboratories
    • 9.1.4. Others

10. Skin Cancer Diagnostics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Skin Cancer Diagnostics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Skin Cancer Diagnostics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Skin Cancer Diagnostics Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Skin Cancer Diagnostics Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Skin Cancer Diagnostics Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Skin Cancer Diagnostics Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. FOUNDATION MEDICINE, INC.
    • 11.2.2. Castle Bioscience
    • 11.2.3. DermTech
    • 11.2.4. bioMerieux Inc.
    • 11.2.5. DermaSensor, Inc.
    • 11.2.6. Quest Diagnostics Incorporated.
    • 11.2.7. NeoGenomics Laboratories
    • 11.2.8. SkylineDx
    • 11.2.9. Abbott
    • 11.2.10. F Hoffmann-La Roche Ltd
    • 11.2.11. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제